<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690248</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-NES-DUM-2007/5</org_study_id>
    <nct_id>NCT00690248</nct_id>
  </id_info>
  <brief_title>Depressive Symptoms in Acute Manic Episode</brief_title>
  <acronym>MM1</acronym>
  <official_title>Prevalence of Depressive Symptoms in Manic Episodes of Bipolar Patients: an Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, non-interventional, transversal, multicenter, open label (No treatment is
      involved). The primary objective is to detect the prevalence of depressive symptoms in
      bipolar patients admitted to a psychiatric Unit due to an acute mania episode. Secondary
      objectives include 1) to evaluate, the relationship between depressive symptoms and severity
      of mania; 2) to evaluate, the relationship between depressive symptoms and anxiety; 3) to
      evaluate, the relationship between depressive symptoms and psychotic symptoms; 4) to
      evaluate, the relationship between depressive symptoms and insight; 5) to evaluate, the
      relationship between depressive symptoms and clinical global impression; 6) to evaluate, the
      relationship between depressive symptoms and previous treatment with antipsychotics (whatever
      the antipsychotic was); 7) to evaluate, the relationship between depressive symptoms and
      length of admission; 8) to evaluate factors (demographic, evolutionâ€¦) which could be involved
      in the presence of depressive symptoms within an acute manic episode; 9) to evaluate, the
      difference on the initial prescription due to the detection of depressive symptoms; 10) to
      evaluate, if exists, differences on the previous psychiatric diagnosis in patients with and
      without depressive symptoms. The primary endpoint is score of the MADRS (Montgomery-Asberg
      Depression Rating Scale) in bipolar patients with acute mania
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Score of the MADRS (Montgomery-Asberg Depression Rating Scale) in bipolar patients with acute mania.</measure>
    <time_frame>once during study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mania symptoms measured with YMRS (Young Mania Rating Scale).</measure>
    <time_frame>once during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety symptoms measures with HARS (Hamilton Anxiety Rating Scale).</measure>
    <time_frame>once during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychotic symptoms measured with BPRS (Brief Psychosis Rating Scale).</measure>
    <time_frame>once during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status and improvement measured with CGI-BP (Clinical Global Impression - Bipolar scale).</measure>
    <time_frame>once during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization, MADRS (6 items)</measure>
    <time_frame>once during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (5 items)</measure>
    <time_frame>once during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale of Unawareness of Mental Disorders (SUMD)</measure>
    <time_frame>once during study</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Bipolar patients admitted to a psychiatric Unit due to an acute mania episode.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        bipolar patients admitted to a psychiatric Unit due to an acute mania episode.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed of Bipolar Disorder based on DSM-IV-TR

          -  Patients admitted to an acute inpatient psychiatric Unit due to an acute manic episode
             (as defined in DSM-IV_TR)

          -  Provision of written informed consent.

          -  Total score in Young Mania Rating Scale &gt;=20

          -  Able to understand and comply with the requirements of the study

        Exclusion Criteria:

          -  Mental retardation

          -  Patients with manic symptoms are due to substance use, based in the investigator
             opinion

          -  Patients with unstable organic diseases, who are not receiving adequate treatment,
             according the investigator opinion.

          -  Participation in a trial with drugs within 4 weeks of enrolment into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alcoy</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Algeciras</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almeria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Palmas</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Logrono</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osuna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plasencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponferrada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan (Alicante)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sant Boi de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teruel</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vitoria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zamora</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>December 7, 2010</last_update_submitted>
  <last_update_submitted_qc>December 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Teresa DÃ­ez, PhD, Local MC Neuroscience Therapeutic Area Manager</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Acute mania</keyword>
  <keyword>Bipolar disorder</keyword>
  <keyword>depressive symptoms</keyword>
  <keyword>mixed mania</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

